1. Home
  2. LQDA vs LGN Comparison

LQDA vs LGN Comparison

Compare LQDA & LGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$37.97

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

LGN

Legence Corp.

N/A

Current Price

$80.45

Market Cap

3.6B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LQDA
LGN
Founded
2004
1963
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.6B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LQDA
LGN
Price
$37.97
$80.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
16
Target Price
$41.00
$57.22
AVG Volume (30 Days)
1.0M
2.1M
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
51.81
N/A
EPS
N/A
N/A
Revenue
$158,320,000.00
N/A
Revenue This Year
$278.87
$53.66
Revenue Next Year
$57.13
$11.99
P/E Ratio
N/A
N/A
Revenue Growth
1031.18
N/A
52 Week Low
$11.85
$28.31
52 Week High
$46.67
$82.54

Technical Indicators

Market Signals
Indicator
LQDA
LGN
Relative Strength Index (RSI) 51.95 75.92
Support Level $35.00 $42.97
Resistance Level $39.19 N/A
Average True Range (ATR) 1.94 3.63
MACD -0.21 0.89
Stochastic Oscillator 36.31 90.40

Price Performance

Historical Comparison
LQDA
LGN

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.

Share on Social Networks: